0000920465-20-000025.txt : 20200204 0000920465-20-000025.hdr.sgml : 20200204 20200204160135 ACCESSION NUMBER: 0000920465-20-000025 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200131 FILED AS OF DATE: 20200204 DATE AS OF CHANGE: 20200204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wellinghoff Darryl CENTRAL INDEX KEY: 0001770350 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36282 FILM NUMBER: 20573613 MAIL ADDRESS: STREET 1: 4550 TOWNE CENTRE COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4550 TOWNE CENTRE COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-207-4264 MAIL ADDRESS: STREET 1: 4550 TOWNE CENTRE COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 wf-form4_158085007789902.xml FORM 4 X0306 4 2020-01-31 0 0000920465 LA JOLLA PHARMACEUTICAL CO LJPC 0001770350 Wellinghoff Darryl C/O LA JOLLA PHARMACEUTICAL COMPANY 4550 TOWNE CENTRE COURT SAN DIEGO CA 92121 0 1 0 0 Chief Commercial Officer Common Stock 2020-01-31 4 A 0 282 5.82 A 8015 D Stock Option (Right to Buy) 6.85 2020-01-31 4 A 0 282 0 A 2030-01-31 Common Stock 282.0 282 D These shares were acquired on 01/31/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. /s/ Ryan Murr, as attorney-in-fact for Darryl Wellinghoff 2020-02-04